Delivery Order SPE2DB25D9312-SPE2DB25FWUWN
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $32,499.90 for Stelara 90mg/ml syringes by the Defense Logistics Agency's Medical Supply Chain on July 24, 2025. The delivery order, which carries no set-aside designation, is scheduled for completion by August 11, 2025, with performance at the contractor's Park Ridge, Illinois location. This award represents a single...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $16,249.95 by the Defense Logistics Agency (DLA) for the supply of Stelara 90 mg/mL syringes. The contract, awarded on July 23, 2025, carries an ultimate completion date of August 13, 2025, and represents a direct delivery order with no set-aside designation. This award falls under DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency for $16,249.95 to supply Stelara 90 mg/mL syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 21, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency valued at $16,249.95 for the supply of Stelara 90 mg/ml syringes. The award, issued on August 18, 2025, with an ultimate completion date of September 9, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $16,249.95 by the Defense Logistics Agency (DLA) on September 8, 2025. The delivery order, which has an ultimate completion date of September 29, 2025, is for Stelara 90 mg/ml syringes—a prescription biologic medication used to treat autoimmune and inflammatory conditions. This award was issued without a set-aside...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $32,499.90 on August 13, 2025, by the Defense Logistics Agency (DLA) for the supply of Stelara 90 mg/mL syringes. This firm fixed-price delivery order, which is scheduled for completion by September 4, 2025, represents a continuation of the company's substantial role as a critical supplier within the federal pharmaceutical supply chain. The...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $16,249.95 on August 19, 2025, for the supply of Stelara 90 mg/ml syringes. The delivery order, which carries a firm fixed price and is not subject to any set-aside designation, is funded by the Defense Logistics Agency's Medical Supply Chain division and must be completed by September 10, 2025. This award represents a single delivery order...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $32,499.90 by the Defense Logistics Agency (DLA) on September 11, 2025. The contract calls for the delivery of Stelara 90 mg/ml syringes, a biologic immunosuppressant medication used to treat autoimmune conditions. This is a firm fixed-price delivery order with an ultimate completion date of October 2, 2025, and no set-aside designation was...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency valued at $97,499.70 for Stelara 90 mg/mL syringes. The contract carries no set-aside designation and has an ultimate completion date of August 18, 2025. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $32,499.90 by the Defense Logistics Agency (DLA) on August 8, 2025. The delivery order covers Stelara 90 mg/mL syringes, a biologic immunosuppressant medication commonly used to treat autoimmune conditions. The award carries no set-aside designation, and the ultimate completion date is scheduled for August 29, 2025. This...
- SPE2DB25D9312Indefinite Delivery Contract
- SPE2DB25D9312-SPE2DB25FWUWNDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a $16,249.95 firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 11, 2025, for the supply of Stelara 90 mg/ml syringes. The contract carries an ultimate completion date of October 2, 2025, and does not utilize a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at $499,999,999 through November 2026, which authorizes the agency to procure a comprehensive range of pharmaceutical products and medical supplies supporting Department of Defense healthcare facilities. Stelara is a biologic immunosuppressant medication commonly used to treat inflammatory conditions including psoriasis, psoriatic arthritis, and Crohn's disease. As a primary supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group has established itself as a critical vendor for delivering prescription drugs and specialty medications to military health facilities nationwide. The company's portfolio encompasses an extensive array of pharmaceutical products ranging from oncology treatments to biologics and medical consumables, positioning it as a strategic partner for the DLA's ongoing medical supply requirements across the Department of Defense healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.2k | 9/11/25 |